IXICO plc Appointment of Shore Capital as Nominated Adviser (3798L)

TIDMIXI

RNS Number : 3798L

IXICO plc

03 October 2016

3 October 2016

IXICO plc

("IXICO" or the "Company")

Appointment of Shore Capital as Nominated Adviser & Sole Broker

IXICO plc (AIM: IXI), the brain health company, announces the appointment of Shore Capital and Corporate Limited as Nominated Adviser and Shore Capital Stockbrokers Limited as sole Broker, (together "Shore Capital"), with immediate effect.

For further information please contact:

 
 IXICO plc 
  Derek Hill, Chief Executive Officer        Tel: +44 20 
  Susan Lowther, Chief Financial Officer     3763 7499 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield            7408 4090 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan/Matthew Moss

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCWGUUCBUPQGPU

(END) Dow Jones Newswires

October 03, 2016 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024